Nexcella, Inc., a subsidiary of Immix Biopharma, Inc , is a Los Angeles, CA based clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Its lead candidate, next generation BCMA-targeted CAR-T NXC-201 for multiple myeloma and AL amyloidosis has produced 92% and 100% response rates in each indication, respectively, as of February 9, 2023 across 58 patients. The company believes NXC-201 has potential to be the world’s first outpatient CAR-T. Its N-GENIUS platform allows it to discover, develop, and manufacture cutting-edge cell therapies for patients in need.